Invivyd reports faster-than-expected enrollment in its DECLARATION study upsized cohort and 22% year-over-year growth for PEMGARDA in Q1 2026.
Invivyd announced accelerated recruitment for its DECLARATION study, upsizing the cohort in early April. Enrollment surpassed internal expectations, prompting the company to slow recruitment to extend the upsized cohort’s timeline.
PEMGARDA sales grew 22% year-over-year in Q1 2026, reflecting continued demand. The company did not disclose specific revenue figures but highlighted operational progress as a key milestone.
Management emphasized the trial’s momentum, noting the upsized cohort’s rapid enrollment as a positive signal for the program’s advancement.